Soligenix issues update letter to shareholders

Soligenix (SNGX) issued an update letter from its President and Chief Executive Officer, Dr. Christopher Schaber. “Top-line results from the actively enrolling 80 patient confirmatory Phase 3 FLASH2 clinical trial for HyBryte in the treatment of early-stage cutaneous T-cell lymphoma are expected in the second half of 2026. Enrollment is currently on track, with an enrollment update coming later this year. This second Phase 3 trial essentially replicates the first Phase 3 study… Top-line results for the last cohort of patients in the Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 in 4Q 2025, where we have already demonstrated the biologic activity and early clinical success of synthetic hypericin in the first two cohorts of patients enrolled in this trial. Top-line results from the Phase 2a proof of concept clinical trial in Behcet’s Disease (BD) with SGX945 in 3Q 2025, where we have previously validated the biologic activity of dusquetide in oral mucositis in patients with head and neck cancer which we believe correlates mechanistically with the aphthous ulcers experienced in patients suffering from BD. Additionally, we continue to follow through on our financing strategies, providing us with sufficient capital and cash runway to meet our goals into 1Q 2026… We remain focused on advancing our development programs in our Specialized BioTherapeutics rare disease business segment… We remain steadfast in our plans for partnership in the ex-U.S. markets and continue to pursue discussions with potential partners with similar reputation and expertise in this therapeutic area.”